ClinicalTrials.gg
RecruitingNCT07201376PPIXUpdated Feb 6, 2026

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically

An observational study in Non-Melanoma Skin Cancer (NMSC) and Benign Skin Growth, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Dartmouth-Hitchcock Medical Center · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
125
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Skin Neoplasms with a site in United States — 64 open to participants now, 98 under way, 7 of them phase 3. Skin Neoplasms · United States.

Planned enrollment
42nd of 80
125 · median 149
Started
2025
with 20 others
Observational
80 of 381
14 open now
Primary completion
2026-11
later than 23 of 96 live
Registered
358th of 381
by date

Among the 381 studies in Skin Neoplasms with a site in United States, this one is the 42nd largest by planned enrollment of the 80 observational ones that give a count, is one of 21 that started in 2025, is one of 80 observational ones, reaches primary completion later than 23 of the 96 other live ones, and was the 358th registered.

Skin Neoplasms

606 studies on the registry are indexed under Skin Neoplasms; 127 are open to participants now.

Browse Skin Neoplasms studies →

Open to participants now

64 of the 381 studies in Skin Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 105 Skin Neoplasms studies recruiting now, 85 (81%) set no upper age limit and 9 (9%) stop at 75 or younger; 15 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Skin Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC).

Read the detailed description

The present study is an open-label, non-randomized, feasibility study aiming to evaluate the ability of a non-significant risk tissue oxygen imager based on protoporphyrin IX (PpIX) delayed fluorescence (DF) for differentiating benign from malignant skin lesions and assessing tumor margins during Mohs micrographic surgery.

03

Conditions studied

  • Non-Melanoma Skin Cancer (NMSC)
  • Benign Skin Growth

Browse trials for

Keywords

  • Benign Skin Growth
  • Non-Melanoma Skin Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants will be enrolled from the Dermatology Clinic where the study is being performed.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥ 18 years of age.
  • Histologic proof of non-melanoma skin cancer. Patients with different skin tones based on the Fitzpatrick Scale, who present with skin growth or lesions and are scheduled for resection.
  • As determined by the enrolling physician or study team member, the patient must have the willingness and ability to understand and comply with study procedures.
  • Women of (WOCBP): Premenopausal females who had at least one menstrual cycle in the past 12-months and capable to become pregnant, must have a negative serum beta-HCG pregnancy test result within seven days prior to start of study.
  • Lesions must measure between 5 mm and 3 cm in diameter.

Exclusion criteria

Exclusion Criteria:

  • Patients who are \<18 years of age
  • Adults who are unable to provide .
  • Known allergy to Ameluz
  • Photosensitivity or photodermatoses or similar conditions.
  • Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol, in the opinion of the investigator
  • Known to porphyrins or to any component of Ameluz, including soya bean phosphatidylcholine.
  • Females who are currently breast-feeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
125 participants (estimated)
Patient registry
No

Interventions

  • DrugAminolevulinic AcidStudies of Aminolevulinic AcidAminolevulinic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    One-time topical application of 10% Ameluz gel for up to 1 hour

  • DeviceProtoporphyrin IX

    Tissue oxygen imaging using protoporphyrin IX (PIX), a non-significant risk device.

06

What researchers measure

Primary outcomes

  1. Detecting cutaneous malignant lesions using a non-invasive technique

    Advancing our understanding of these cancers and developing effective strategies for diagnosis. The study will use aminolaevulinic acid (ALA) as a source of protoporphyrin IX (PpIX) to allow the detection of hypoxia signal. More specifically, the oxygen imager gathers the delayed fluorescence (DF) of PpIX, which intensity is inversely proportional to tissue mitochondrial oxygen content. This provides qualitative contrast on hypoxic regions with submillimeter spatial resolution. Transient hypoxia is a clear indicator of tumor tissue. We will validate the combination of hypoxia imaging with palpation as a non-invasive technique to detect cutaneous malignant lesions.

    Time frame: Six months after the first enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — There is no plan to share identifiable data. All data will be owned and maintained by Dartmouth.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2025
First posted
Oct 1, 2025
StartActual
Nov 14, 2025
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2027
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07201376
Collaborators
Dartmouth College
Responsible party
Michael S. Chapman (Principal Investigator, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Oct 1, 2025
Start date
Nov 14, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2027 (estimated)
Last update
Feb 6, 2026

Study contacts

Dylan L Parker, MD
Contact
Dylan.J.Parker@Hitchcock.org
603-653-2209
Staci Shaw
Contact
Staci.L.Shaw@Hitchcock.org
603-650-3693
Michael Chapman, MD
principal investigator · Dartmouth

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion